Halda reveals first clinical data of RIPTAC drug in prostate cancernews2025-10-24T18:13:58+00:00October 24th, 2025|Endpoints News|
Philly is on Lilly’s radar for next Gateway Labs sitenews2025-10-24T17:20:51+00:00October 24th, 2025|Endpoints News|
Biogen pays $70M upfront to Vanqua Bio for immunology drugnews2025-10-24T14:29:40+00:00October 24th, 2025|Endpoints News|
Eli Lilly to seek Olumiant approval in adolescents with alopecianews2025-10-24T14:17:22+00:00October 24th, 2025|Endpoints News|
Zai Lab shares Phase 1 data for lung cancer drug that could spar with Amgen’s Imdelltranews2025-10-24T13:00:14+00:00October 24th, 2025|Endpoints News|
Sanofi’s Dupixent sales continue to deliver as ‘negative buzz’ impacts vaccine franchisenews2025-10-24T10:49:57+00:00October 24th, 2025|Endpoints News|
FDA brings GSK’s Blenrep back to the market in multiple myelomanews2025-10-23T20:27:08+00:00October 23rd, 2025|Endpoints News|
Post-Hoc: Why we tracked pharma’s private jet flights to DCnews2025-10-23T17:02:11+00:00October 23rd, 2025|Endpoints News|
Merck KGaA to end API work at Irish plant after ‘strategic portfolio review’news2025-10-23T16:24:04+00:00October 23rd, 2025|Endpoints News|
Ventyx’s stock soars on cardiovascular data for NLRP3 drugnews2025-10-23T14:31:10+00:00October 23rd, 2025|Endpoints News|
